Cure8 research brief
Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.
Clinicians who monitor IBD patients, researchers studying IBD biomarkers, and adult patients interested in non-invasive disease monitoring.
This retrospective observational study of 36 adults with IBD (21 Crohn’s disease, 15 ulcerative colitis) compared fecal calprotectin, hemogram-derived ratios (e.g., NLR), albumin-integrating nutritional scores (PNI, PALBI), and liver fibrosis indices (APRI, FIB-4) against endoscopic severity.
Fecal calprotectin had the strongest diagnostic performance for mucosal inflammation and differentiating UC from CD. Albumin-containing scores and simple blood-ratio indices reflected systemic inflammation better than hepatic fibrosis scores but showed only moderate accuracy and are not sufficient alone to guide care.
The study is retrospective and small, and patients were receiving biologic therapy, which may affect biomarker levels. The authors recommend using these non-invasive markers as adjuncts alongside endoscopy within a personalized, multiparametric approach rather than as standalone diagnostics.
this brief is grounded in the article abstract provided by the Journal of Gastrointestinal and Liver Diseases (structured content depth: abstract); Cure8 did not review the full study beyond the supplied text.
Small sample size, retrospective design, and the fact that participants were on biologic therapy limit how broadly the results can be applied. The is derived from the journal abstract and should not be interpreted as a comprehensive review of the full paper.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
Vitamin D supplementation is commonly considered in people with IBD because deficiency is frequent and low vitamin D may relate to inflammation.
